
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn
The Director of Formulation Development will assist in the development of late-stage oral drug product development and commercial manufacturing strategies to support Kymera’s small molecule pipeline from Phase 2/3 through commercialization.
This is an opportunity to join a fast-paced, innovative biotech environment where bold ideas and collaboration drive breakthroughs. As a member of the CMC team, you will develop and implement robust, scalable manufacturing processes for late-stage manufacturing and eventual commercialization.
The ideal candidate will bring deep expertise in oral solid dose formulation development and manufacturing within a GMP environment, strong project leadership capabilities, and a passion for working in a dynamic, mission-driven culture focused on delivering life-changing medicines. This role will work cross-functionally with CMC, Regulatory, Quality and external partners to deliver high-quality drug products aligned with program timelines.
Equal Employment Opportunity
Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.
Compensation

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.